The UK authorised a GLP-1 tablet
On 10 August 2026 the UK medicines regulator authorised orforglipron, sold as Foundayo. It is the first country in Europe to authorise this GLP-1 tablet for weight management and type 2 diabetes.
Orforglipron is a small-molecule GLP-1, not a peptide. It is a once-daily tablet. It can be taken at any time of day with no food or water restrictions. It is prescription-only.
It is authorised for weight loss and weight maintenance in adults in the UK with a BMI of 30 or above, or a BMI of 27 to 30 plus at least one weight-related comorbidity. It is also authorised to improve glycaemic control in insufficiently controlled type 2 diabetes.
Julian Beach of the MHRA said it will be kept under close review like other GLP-1s. It is not currently available via the NHS. NICE will evaluate.
Common side effects listed by the MHRA: nausea, constipation, diarrhoea, vomiting, dyspepsia, abdominal pain.
The MHRA said buying GLP-1 medicines from unregulated sellers carries serious health risks, and that it is against the law to promote any prescription-only medication direct to the public. Authorisation was granted on 10 August 2026 to Eli Lilly.
This is one authorised product in one country. It is not a how-to, and it is not a U.S. approval. See also Three kinds of peptides.
Citations
Peptide Vault is a personal log and research library. Not medical advice, not a pharmacy, not a shop. We do not tell you what to take, how to mix it, or where to get it. No dosing. No where-to-buy. No mix tutorials. No heal/optimize claims.